Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lynk Pharmaceuticals Announces Positive Results for LNK01004 in Atopic Dermatitis
Details : LNK01004 ointment is a topical, skin-restricted soft pan JAK inhibitor intended for the treatment of atopic dermatitis and other related conditions.
Product Name : LNK01004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GT20029, a proteolysis targeting chimera (PROTAC) compound, is a topical AR degrader causing shrinkage and miniaturization of hair follicles caused by the activation of AR signaling pathway. It is being developed for acne vulgaris and androgenetic alopec...
Product Name : GT20029
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2023
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TDM-180935
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TDM–180935 is a small molecule drug candidate being developed as a topical drug for treatment of Atopic Dermatitis. As a potent JAK1/Tyk2 small molecule inhibitor, it may offer significant advantages regarding efficacy and safety compared to existing t...
Product Name : TDM-180935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : TDM-180935
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNK01004 ointment is a topical, skin-restricted JAK inhibitor, primarily acting on the skin with rapid onset of action and minimal systemic exposure. It has the potential to be a first-in-class treatment with skin-restricted properties.
Product Name : LNK01004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2023
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNK01004 ointment is a topical, skin-restricted soft pan JAK inhibitor intended for the treatment of psoriasis and other related conditions. LNK01004 has the potential to be a first-in-class treatment.
Product Name : LNK01004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ICP-488
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ICP-488 is a potent and selective TYK2 allosteric inhibitor, which is developed for the treatment of psoriasis and other autoimmune diseases. By binding the JH2 domain.
Product Name : ICP-488
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2023
Lead Product(s) : ICP-488
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TDM-180935
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TDM-180935 is a JAK1/Tyk2 inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of atopic dermatitis.
Product Name : TDM-180935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : TDM-180935
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
Details : BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Product Name : BSI-045B
Product Type : Antibody
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Bosakitug
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CS32582
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
Details : CS32582 is a novel small molecule and highly selective allosteric inhibitor of Tyrosine Kinase 2 (TYK2). It got approval for conducting clinical trials for the treatment of psoriasis.
Product Name : CS32582
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : CS32582
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GT20029 is a topical androgen receptor (AR) degrader using Kintor Pharma's PROTAC platform. GT20029 can effectively block the shrinkage and miniaturization of hair follicles caused by activated AR signaling pathway.
Product Name : GT20029
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable